Key facts
- This page summarizes Robert N. Weingarten's Form 4 filing for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).
- 1 reported transaction and 2 derivative rows are listed below.
- Accepted by SEC: 09 Nov 2022, 16:00.
Robert N. Weingarten - 06 Nov 2022 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
- Reporting relationship
- Vice President and CFO
- Issuer ticker
- LIXT
- Reported as of
- 06 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Nov 2022, 16:00:33 UTC
- Prior SEC filing
- 21 Jun 2022
- Next SEC filing
- 05 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Weingarten
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert N. Weingarten filed Form 4 for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) on 09 Nov 2022.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LIXT
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 06 Nov 2022
- Ownership
- Direct
- Underlying class
- Common
- Underlying amount
- 200,000
- Exercise price
- $2.00
- Footnotes
- F1
LIXT
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 58,333
- Date
- 06 Nov 2022
- Ownership
- Direct
- Underlying class
- Common
- Underlying amount
- 58,333
- Exercise price
- $7.14
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On November 6, 2022, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock, exercisable for a period of 5 years at $2.00 per share, vesting 25% on the issuance date, and 25% on each anniversary date thereafter until fully vested, subject to continued service.